[ad_1]
Post-Oxford AstraZeneca, India Biotech’s crown vaccine has been approved by an expert panel made up of the Indian Ministry of Health.
According to sources from the Indian news agency.
However, authorization has only been granted for “controlled emergency applications”. Now waiting for the final clearance. Final authorization will be granted by the Drug Enforcement General of India (DCGI). The vaccine will be administered as soon as it is approved by the drug regulator.
The vaccine from Hyderabad Biotech, a Hyderabad-based vaccine manufacturer, has shown promising results from the beginning. Satisfactory results were also observed in the experimental application. Therefore, the vaccine has been approved by the expert panel for controlled emergency use.
India Biotech presented detailed information on the vaccine to the DGCI on Saturday (January 2) afternoon. The vaccine can now be used in an emergency in India only after obtaining final approval from DCGI.
When analyzing the application of Bharat Biotech, the panel of experts discussed that Bharat Biotech has conducted clinical trials on 25,600 citizens of the country. Of these, 23,000 people have been vaccinated. There are also people with comorbidity, in whom it is understood that it is safe. But it will take a little longer to fully understand how effective it is.
India’s Union Health Minister Prakash Javadekar said on Friday that the three vaccines were still awaiting approval by a panel set up by the Union Health Ministry. One of them is Kovacin, one is Cadillac Zykov-D and the other is Sputnik-V from Russia.
Source: Anandabazar
Bangladesh time: 2100 hours, January 2, 2020
MJF
News, information, images, photographs, diagrams, videos, audio content posted / broadcast by banglanews24.com may not be used without prior permission under copyright law.
[ad_2]
